Current Report Articles
AHA Letter Urges HHS to Take Action Against Drug Manufacturers for Limiting the Distribution of 340B Drugs

AHA Logo (Aug. 7, 2020) – The American Hospital Association recently sent a letter urging the U.S. Department of Health and Human Services secretary to direct the Health Resources and Services Administration to take action to stop three drug manufacturers — Eli Lilly, Merck and Sanofi — from limiting the distribution of 340B drugs to 340B covered entities. These drug manufacturers have taken separate actions to either limit the distribution of 340B drugs or require 340B covered entities to provide claims-level data for investigatory purposes if that 340B covered entity uses a contract pharmacy arrangement.

AHA requests drug manufacturers stop this activity, noting, "340B hospitals continue to struggle to meet the demands of the COVID-19 public health emergency, and it is outrageous that in the middle of a pandemic, hospitals are facing added challenges to the drug supply chain brought on by the actions of these major drug manufacturers."
--Steve Poage